Baxter gammagard liquid receives FDA nod
Gammagard liquid is indicated as replacement therapy for primary humoral immunodeficiency in adult and pediatric patients two years of age or over. Baxter gammaglobulin trials medical director Richard
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.